- Medicaid Fraud Control Units: investigation and prosecution of fraud and beneficiary abuse in Medicaid personal care services1
- Medicaid demonstrations: federal action needed to improve oversight of spending : report to the Chairman, Committee on Finance, U.S. Senate1
- Medicaid personal care services: more harmonized program requirements and better data are needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Medicaid program integrity: CMS should build on current oversight efforts by further enhancing collaboration with states : report to the Chairman, Committee on Finance, U.S. Senate1
- Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices1
- Medicare advantage: CMS should use data on disenrollment and beneficiary health status to strengthen oversight : report to Congressional Requesters1
- Medicare and Medicaid: CMS needs to fully align its antifraud efforts with the fraud risk framework : report to Congressional addressees1
- Medicare market shares of mail-order diabetes test strips from October through December 20161
- Medicare payments for clinical diagnostic laboratory tests in 2016: year 3 of baseline data1
- Medicare program shared savings accountable care organizations have shown potential for reducing spending and improving quality1
- Medicare: CMS should evaluate providing coverage for disposable medical devices that could substitute for durable medical equipment : report to Congressional committees1
- Navigating recovery: health care financing and delivery systems in Puerto Rico and US Virgin Islands1
- Newborn health: federal action needed to address neonatal abstinence syndrome : report to Congressional addressees1
- Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry1
- OHRP generally conducted its compliance activities independently, but changes would strengthen its independence1
- OHRP should inform potential complainants of how they can seek whistleblower protections: 1
- Opioid use disorders: HHS needs measures to assess the effectiveness of efforts to expand access to medication-assisted treatment : report to majority leader, U.S. Senate1
- Part D plans generally include drugs commonly used by dual eligibles: 20171
- Pediatric information for x-ray imaging device premarket notifications: guidance for industry and Food and Drug Administration staff1